The Board of Zelda Therapeutics Ltd provide an operational update to accompany its Appendix 4C, released today, for the three month period to 31 March 2018.
US Autism Observational Study Receives IRB Approval
The Company announced it has received approval from the Institutional Review Board (IRB) for its study of the pharmacology of cannabinoids in the treatment of paediatric autism patients, to be conducted at the USA-based Children’s Hospital of Philadelphia (CHOP).
The IRB is equivalent to Human Research Ethics Approval in Australia and the approval essentially allows the research to commence within the parameters of the approved trial protocols.
This is a potentially key milestone study in ongoing medicinal cannabis research in a clinical environment.
Establishment of US OTCQB Share Trading Facility
The Company’s ordinary shares have been approved for trading on the OTCQB Venture Market in the United States of America under the symbol “ZLDAF”. The OTCQB is a US-based trading platform operated by OTC Markets Group in New York. The OTCQB Venture Market is for early-stage and developing USA and international companies. This forms part of our ongoing strategy to introduce Zelda Therapeutics to a broader international audience and this facility will provide greater visibility, better access to the US investment community, and improved convenience of trading in Zelda’s ordinary shares.
Expansion of Pancreatic Cancer Research Programme
Subsequent to quarter end, Zelda announced it has expanded its pre-clincial pancreatic cancer research programme with Curtin University. The new research will focus on in vivo animal studies to investigate the effect of a range of Zelda’s formulations in combination with existing chemotherapy agents Abraxane and Gemcitabine. Studies will mirror current human treatment protocols to generate highly relevant data for potential future human clinical trials.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.